Fujii M, Fujii T, Saito K, Kobayashi Y, Takahashi N, Yoshikumi C, Taguchi T
Biomedical Research Laboratories, Kureha Chemical Industry Co., Ltd., Tokyo, Japan.
In Vivo. 1987 May-Jun;1(3):151-5.
Tumor-bearing rats with and without splenectomy were used for an immunological study on the effects of PSK, an immunomodulator, with respect to the survival rate and serum level of immunosuppressive (IS) substance. There was no significant difference in survival rates between the tumor-resected and tumor-resected-plus-splenectomy groups. The IS substance level in the former group was higher than that in the latter group. Normalization of IS substance level and prolongation of survival were observed in the group administered PSK. PSK can be effective in combination with surgical treatment.
将有肿瘤和无肿瘤的大鼠进行脾切除，用于免疫研究免疫调节剂PSK对生存率和免疫抑制（IS）物质血清水平的影响。肿瘤切除组和肿瘤切除加脾切除组的生存率无显著差异。前一组的IS物质水平高于后一组。给予PSK的组中观察到IS物质水平正常化和生存期延长。PSK与手术治疗联合可能有效。
